Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer

Control of Regulatory T Cell Development by the Transcription Factor Foxp3

2003 • 7,902 citations

Enhancement of Antitumor Immunity by CTLA-4 Blockade

1996 • 3,585 citations

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1995 • 2,842 citations

THE B7 FAMILY REVISITED

2005 • 2,239 citations

CD4+CD25+ suppressor T cells: more questions than answers

2002 • 2,202 citations

CTLA-4 can function as a negative regulator of T cell activation

1994 • 2,107 citations

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

1995 • 2,090 citations

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1996 • 1,908 citations

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

2003 • 1,564 citations

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

2002 • 1,529 citations

Modulation of tryptophan catabolism by regulatory T cells

2003 • 1,323 citations

A new member of the immunoglobulin superfamily—CTLA-4

1987 • 1,214 citations

Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

2004 • 1,213 citations

CTLA-4–Ig regulates tryptophan catabolism in vivo

2002 • 1,150 citations

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1992 • 1,076 citations

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

2001 • 1,033 citations

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

1999 • 1,000 citations

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

2005 • 997 citations

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

2003 • 981 citations

CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy

2001 • 964 citations

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

2004 • 834 citations

Management of Cutaneous Melanoma

2004 • 830 citations

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

2006 • 812 citations

Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells

2001 • 759 citations

Molecular Basis of T Cell Inactivation by CTLA-4

1998 • 678 citations

HUMAN T CELL RESPONSES AGAINST MELANOMA

2005 • 638 citations

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

1987 • 615 citations

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

2005 • 584 citations

A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION

2005 • 497 citations

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

2005 • 486 citations

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells

2012 • 462 citations

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+regulatory T cells

2005 • 451 citations

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

2004 • 432 citations

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

2000 • 421 citations

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

1992 • 394 citations

CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma

1998 • 375 citations

Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer

2005 • 350 citations

Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

2005 • 331 citations

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials

2003 • 323 citations

Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease

2004 • 322 citations

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

2001 • 307 citations

Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy

2002 • 303 citations

Human Ig superfamily CTLA‐4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA‐4 cytoplasmic domains

1988 • 296 citations

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

2005 • 293 citations

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase

2004 • 290 citations

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

2006 • 261 citations

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

2003 • 257 citations

E3 ubiquitin ligases as T cell anergy factors

2004 • 224 citations

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy

1999 • 223 citations

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

2006 • 171 citations

In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance

1999 • 157 citations

Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

2006 • 147 citations

Cytokine-Based Therapy and Biochemotherapy for Advanced Melanoma

2006 • 146 citations

Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques

2003 • 128 citations

Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy

2004 • 119 citations

Expression of CTLA‐4 by Human Monocytes

2002 • 88 citations

IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE).

2002 • 87 citations

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.

2005 • 79 citations

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3[+]CD25[+]CD4[+] regulatory T cells

2006 • 70 citations

Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8+ T Cells Independently of CD4+T Cell Help

1999 • 69 citations

CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen

2001 • 50 citations

CTLA4 Blockade Maximizes Antitumor T-Cell Activation by Dendritic Cells Presenting Idiotype Protein or Opsonized Anti-CD20 Antibody-Coated Lymphoma Cells

2002 • 42 citations

The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFNγ

2001 • 39 citations

Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.

2004 • 33 citations

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

2005 • 30 citations

Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma

2006 • 14 citations

CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease

2004 • 13 citations

Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab

2006 • 6 citations

Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206)

2006 • 4 citations